RÉSUMÉ
Besides its established functions in intermediary metabolism and developmental processes, the nuclear receptor peroxisome proliferator-activated receptor ß/δ (PPARß/δ) has a less defined role in tumorigenesis. In the present study, we have identified a function for PPARß/δ in cancer cell invasion. We show that two structurally divergent inhibitory ligands for PPARß/δ, the inverse agonists ST247 and DG172, strongly inhibit the serum- and transforming growth factor ß (TGFß)-induced invasion of MDA-MB-231 human breast cancer cells into a three-dimensional matrigel matrix. To elucidate the molecular basis of this finding, we performed chromatin immunoprecipitation sequencing (ChIP-Seq) and microarray analyses, which identified the gene encoding angiopoietin-like 4 (ANGPTL4) as the major transcriptional PPARß/δ target in MDA-MB-231 cells, previously implicated in TGFß-mediated tumor progression and metastatic dissemination. We show that the induction of ANGPTL4 by TGFß and other oncogenic signals is strongly repressed by ST247 and DG172 in a PPARß/δ-dependent fashion, resulting in the inhibition of ANGPTL4 secretion. This effect is attributable to these ligands' ability to induce a dominant transcriptional repressor complex at the site of transcription initiation that blocks preinitiation complex formation through an histone deacetylase-independent, non-canonical mechanism. Repression of ANGPTL4 transcription by inverse PPARß/δ agonists is functionally linked to the inhibition of cancer cell invasion into a three-dimensional matrix, as (i) invasion of MDA-MB-231 cells is critically dependent on ANGPTL4 expression, (ii) recombinant ANGPTL4 stimulates invasion, and (iii) reverses the inhibitory effect of ST247 and DG172. These findings indicate that a PPARß/δ-ANGPTL4 pathway is involved in the regulation of tumor cell invasion and that its pharmacological manipulation by inverse PPARß/δ agonists is feasible.
Sujet(s)
Acrylonitrile/analogues et dérivés , Angiopoïétines/génétique , Récepteur PPAR delta/physiologie , Pipérazines/pharmacologie , Transduction du signal , Sulfonamides/pharmacologie , Thiophènes/pharmacologie , Acrylonitrile/pharmacologie , Protéine-4 similaire à l'angiopoïétine , Angiopoïétines/métabolisme , Sites de fixation , Lignée cellulaire tumorale , Mouvement cellulaire , Régulation de l'expression des gènes tumoraux , Histone deacetylases/métabolisme , Humains , Invasion tumorale , Récepteur PPAR delta/agonistes , Récepteurs X des rétinoïdes/métabolisme , Initiation de la transcription/effets des médicaments et des substances chimiques , Facteur de croissance transformant bêta/physiologieRÉSUMÉ
WHAT IS KNOWN AND OBJECTIVE: A mixture of morphine and droperidol is a well-established antiemetic for reducing the risk of postoperative nausea and vomiting. A mixture of piritramide and droperidol has not yet been evaluated in this context. Our objectives were to develop a high-performance liquid chromatographic assay for piritramide and droperidol in 0·9% saline, and to establish their stability under defined storage conditions. METHODS: The separation and assay of both drugs were attempted by high performance liquid chromatography (HPLC) using a RP-select B column and a mobile phase of 57:43% v/v methanol-monosodium phosphate solution 0·05 M at a flow rate of 1·2 mL/min. UV detection at 205 and 246 nm for piritramide and droperidol were used, respectively. RESULTS AND DISCUSSION: The HPLC method was successful. Linearity was shown for piritramide from 0·075 to 0·013 mg/mL and for droperidol from 0·8 to 0·2 mg/mL. The intra- and inter-day relative standard deviation (RSD, %) was 0·27% and 0·54% for piritramide and droperidol, respectively. The two drugs were stable for at least 72 h when stored under ambient light at room temperature. WHAT IS NEW AND CONCLUSION: Seventy-five milligrams piritramide and 2·5 mg droperidol diluted to 50 ml with 0·9% saline should be suitable for clinical use. At this dilution, a Dipidolor(®) and Xomolix(®), mixture, was stable when stored under ambient light exposure at room temperature for at least 72 h.
Sujet(s)
Analgésie autocontrôlée , Analgésiques morphiniques/analyse , Antiémétiques/analyse , Dropéridol/analyse , Piritramide/analyse , Vomissements et nausées postopératoires/traitement médicamenteux , Vomissements et nausées postopératoires/prévention et contrôle , Chromatographie en phase liquide à haute performance , Stabilité de médicament , Humains , Solutions pharmaceutiques/analyse , Vomissements et nausées postopératoires/induit chimiquementRÉSUMÉ
The objective of the current study was to characterize the influence of high density lipoproteins (HDL) on processes related to the vascular recruitment of human monocytes, which may contribute to the anti-atherogenic properties of these lipoproteins. We show that HDL(3) and apo AI inhibit the following processes in primary human monocytes: (1) M-CSF induced cell spreading; (2) M-CSF stimulated expression of surface molecules involved in adhesion, migration, and scavenging; (3) fMLP induced chemotaxis. These processes are obviously modulated by the regulation of cellular cholesterol pools as indicated by the following findings. In Tangier monocytes with defective apo AI induced cholesterol efflux, apo AI had no influence on the spreading response. In control cells, stimulation of cholesterol efflux by p-cyclodextrin mimicked the effect of apo AI and HDL(3) on spreading and chemotaxis, whereas cholesterol loading with enzymatically modified LDL (E-LDL) showed the opposite effect. Finally, a similar inverse regulation by E-LDL and apo AI/HDL(3) was also observed in regard to the surface expression of beta(1)- and beta(2)-integrins as well as the hemoglobin/haptoglobin scavenger receptor CD163 and the Fcgamma-IIIaR CD16. CDC42 was identified as a potential downstream target linking changes in cellular cholesterol content to monocyte spreading and chemotaxis. Thus, CDC42 antisense markedly reduced spreading and, in parallel with their influence on monocyte spreading, HDL(3), apo AI and p-cyclodextrin down-regulated CDC42 expression while E-LDL had the inverse effect. The apo AI induced decrease of CDC42 protein expression was paralleled by the reduction of active GTP-bound CDC42. In summary, we provide evidence that HDL(3) and apo AI are able to inhibit processes in primary human monocytes, which are related to the recruitment of monocytes into the vessel wall and probably involve regulation of cellular cholesterol pools and CDC42 function.
Sujet(s)
Apolipoprotéine A-I/métabolisme , Cholestérol HDL/métabolisme , Facteur de stimulation des colonies de macrophages/pharmacologie , Monocytes/effets des médicaments et des substances chimiques , Monocytes/physiologie , Protéine G cdc42/métabolisme , Apolipoprotéine A-I/génétique , Technique de Western , Cellules cultivées , Cholestérol HDL/génétique , Cytométrie en flux , Expression des gènes , Humains , Valeurs de référence , Sensibilité et spécificité , Maladie de Tangier/métabolisme , Protéine G cdc42/génétiqueRÉSUMÉ
We report the identification of the full-length cDNA for a novel ATP-binding cassette (ABC) transporter from human macrophages. The mRNA is of 6.8 kb size and contains an open reading frame encoding a polypeptide of 2146 amino acids with a calculated molecular weight of 220 kDa. The predicted protein product is composed of two transmembrane domains and two nucleotide binding folds indicating that it pertains to the group of full-size ABC transporters. The novel transporter shows highest protein sequence homology with the recently cloned human cholesterol and phospholipid exporter ABCA1 (54%) and the human retinal transporter ABCR (49%), both members of the ABC transporter subfamily A. In accordance with the currently proposed classification, the novel transporter was designated ABCA7. ABCA7 mRNA was detected predominantly in myelo-lymphatic tissues with highest expression in peripheral leukocytes, thymus, spleen, and bone marrow. Expression of ABCA7 is induced during in vitro differentiation of human monocytes into macrophages. In macrophages, both the ABCA7 mRNA and protein expression are upregulated in the presence of modified low density lipoprotein and downregulated by HDL(3). Our results suggest a role for ABCA7 in macrophage transmembrane lipid transport.
Sujet(s)
Transporteurs ABC/génétique , Transporteurs ABC/métabolisme , Stérols/métabolisme , Séquence d'acides aminés , Séquence nucléotidique , Différenciation cellulaire , Amorces ADN/génétique , ADN complémentaire/génétique , Femelle , Humains , Techniques in vitro , Macrophages/cytologie , Macrophages/métabolisme , Mâle , Données de séquences moléculaires , Grossesse , ARN messager/génétique , ARN messager/métabolisme , Similitude de séquences d'acides aminés , Distribution tissulaireRÉSUMÉ
Mutations in the gene encoding ATP-binding cassette transporter 1 ( ABC1) have been reported in Tangier disease (TD), an autosomal recessive disorder that is characterized by almost complete absence of plasma high-density lipoprotein (HDL), deposition of cholesteryl esters in the reticulo-endothelial system (RES) and aberrant cellular lipid trafficking. We demonstrate here that mice with a targeted inactivation of Abc1 display morphologic abnormalities and perturbations in their lipoprotein metabolism concordant with TD. ABC1 is expressed on the plasma membrane and the Golgi complex, mediates apo-AI associated export of cholesterol and phospholipids from the cell, and is regulated by cholesterol flux. Structural and functional abnormalities in caveolar processing and the trans-Golgi secretory pathway of cells lacking functional ABC1 indicate that lipid export processes involving vesicular budding between the Golgi and the plasma membrane are severely disturbed.
Sujet(s)
Transporteurs ABC/génétique , Transporteurs ABC/métabolisme , Membrane cellulaire/métabolisme , Glycoprotéines/génétique , Glycoprotéines/métabolisme , Appareil de Golgi/métabolisme , Métabolisme lipidique , Maladie de Tangier/génétique , Maladie de Tangier/métabolisme , Membre-1 de la sous-famille A des transporteurs à cassette liant l'ATP , Animaux , Apoptose , Plaquettes/métabolisme , Cholestérol/sang , Cholestérol/métabolisme , Cholestérol HDL/sang , Fibroblastes/métabolisme , Génotype , Humains , Muqueuse intestinale/anatomopathologie , Muqueuse intestinale/ultrastructure , Intestin grêle/anatomopathologie , Souris , Souris knockout , Données de séquences moléculaires , Phospholipides/métabolisme , Triglycéride/sangRÉSUMÉ
Excessive uptake of atherogenic lipoproteins such as modified low-density lipoprotein complexes by vascular macrophages leads to foam cell formation, a critical step in atherogenesis. Cholesterol efflux mediated by high-density lipoproteins (HDL) constitutes a protective mechanism against macrophage lipid overloading. The molecular mechanisms underlying this reverse cholesterol transport process are currently not fully understood. To identify effector proteins that are involved in macrophage lipid uptake and release, we searched for genes that are regulated during lipid influx and efflux in human macrophages using a differential display approach. We report here that the ATP-binding cassette (ABC) transporter ABCG1 (ABC8) is induced in monocyte-derived macrophages during cholesterol influx mediated by acetylated low-density lipoprotein. Conversely, lipid efflux in cholesterol-laden macrophages, mediated by the cholesterol acceptor HDL(3), suppresses the expression of ABCG1. Immunocytochemical and flow cytometric analyses revealed that ABCG1 is expressed on the cell surface and in intracellular compartments of cholesterol-laden macrophages. Inhibition of ABCG1 protein expression using an antisense strategy resulted in reduced HDL(3)-dependent efflux of cholesterol and choline-phospholipids. In a comprehensive analysis of the expression and regulation of all currently known human ABC transporters, we identified an additional set of ABC genes whose expression is regulated by cholesterol uptake or HDL(3)-mediated lipid release, suggesting a potential function for these transporters in macrophage lipid homeostasis. Our results demonstrating a regulator function for ABCG1 in cholesterol and phospholipid transport define a biologic activity for ABC transporters in macrophages.
Sujet(s)
Transporteurs ABC/physiologie , Cholestérol/métabolisme , Protéines de Drosophila , Macrophages/métabolisme , Phospholipides/métabolisme , Membre-1 de la sous-famille G des transporteurs à cassette liant l'ATP , Transporteurs ABC/analyse , Transporteurs ABC/génétique , Animaux , Transport biologique , Cellules cultivées , Protéines de l'oeil/génétique , Femelle , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Humains , Immunohistochimie , Protéines d'insecte/génétique , Cinétique , Lipoprotéines HDL/pharmacologie , Lipoprotéines LDL/pharmacologie , Macrophages/composition chimique , Macrophages/effets des médicaments et des substances chimiques , Mâle , Monocytes/composition chimique , Monocytes/effets des médicaments et des substances chimiques , Monocytes/métabolisme , Oligonucléotides antisens/pharmacologie , ARN messager/génétique , ARN messager/métabolisme , Distribution tissulaireRÉSUMÉ
Tangier disease (TD) is an autosomal recessive disorder of lipid metabolism. It is characterized by absence of plasma high-density lipoprotein (HDL) and deposition of cholesteryl esters in the reticulo-endothelial system with splenomegaly and enlargement of tonsils and lymph nodes. Although low HDL cholesterol is associated with an increased risk for coronary artery disease, this condition is not consistently found in TD pedigrees. Metabolic studies in TD patients have revealed a rapid catabolism of HDL and its precursors. In contrast to normal mononuclear phagocytes (MNP), MNP from TD individuals degrade internalized HDL in unusual lysosomes, indicating a defect in cellular lipid metabolism. HDL-mediated cholesterol efflux and intracellular lipid trafficking and turnover are abnormal in TD fibroblasts, which have a reduced in vitro growth rate. The TD locus has been mapped to chromosome 9q31. Here we present evidence that TD is caused by mutations in ABC1, encoding a member of the ATP-binding cassette (ABC) transporter family, located on chromosome 9q22-31. We have analysed five kindreds with TD and identified seven different mutations, including three that are expected to impair the function of the gene product. The identification of ABC1 as the TD locus has implications for the understanding of cellular HDL metabolism and reverse cholesterol transport, and its association with premature cardiovascular disease.
Sujet(s)
Transporteurs ABC/génétique , Glycoprotéines/génétique , Mutation , Maladie de Tangier/génétique , Membre-1 de la sous-famille A des transporteurs à cassette liant l'ATP , Transporteurs ABC/métabolisme , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Séquence nucléotidique , Enfant d'âge préscolaire , Cholestérol HDL/déficit , Cholestérol HDL/métabolisme , Chromosomes humains de la paire 9 , Femelle , Glycoprotéines/métabolisme , Humains , Mâle , Adulte d'âge moyen , Modèles génétiques , Données de séquences moléculaires , PedigreeRÉSUMÉ
BACKGROUND: Meconium aspiration syndrome (MAS) is still a condition associated with a high mortality, and many patients require extracorporeal membrane oxygenation (ECMO) as rescue therapy. Beneficial effects of surfactant and perflubron lavage have been reported. However, pure surfactant supplementation has not been proven to be beneficial in the most severe forms of MAS. This study was performed to demonstrate an improvement in oxygenation in neonates transferred for ECMO and fulfilling ECMO criteria with a saline lavage and surfactant resupplementation. METHODS: Twelve newborns with MAS [gestational age 36-40 weeks, mean birth weight 3200 g, age 4-16 h, oxygenation index (OI) > 40] transferred for ECMO therapy were treated with saline lavage (5-10 cm3/kg body weight, as long as green colored retrieval was observed) and resupplementation with bovine surfactant (Alveofact, Boehringer, Ingelheim, Germany). The OI at admission and 3 h after this procedure was compared using the t-test for paired samples. ECMO was available as rescue therapy at all times. RESULTS: The OI decreased from 49.4 (SD +/- 13.3) to 27.4 (SD +/- 7.3), P < 0.01. The decrease was sustained in nine patients, three patients required ECMO and all patients survived. CONCLUSIONS: As MAS is a condition with parenchymal damage, pulmonary hypertension and obstructive airway disease, no simple causative therapy is possible. Surfactant application after removal of meconium by extensive lavage is feasible as long as 16 h after birth even in infants considered for ECMO therapy; it might reduce the necessity of ECMO.
RÉSUMÉ
In normal young pigs two labeling procedures were evaluated to study the production of lymphocytes in mesenteric lymph nodes. Tritiated thymidine was injected either into the superior mesenteric artery or directly into the lymph nodes. There was a high rate of lymphocyte production and a considerable export of newly-formed small lymphocytes. The distribution to lymphoid organs and the appearance of labeled lymphocytes in the blood were comparable after both techniques. The intranodal labeling resulted in a more selective labeling and thus was found to be the superior method for quantitative studies.